| First Author | Li X | Year | 2017 |
| Journal | J Bone Miner Res | Volume | 32 |
| Issue | 4 | Pages | 834-845 |
| PubMed ID | 27505721 | Mgi Jnum | J:312649 |
| Mgi Id | MGI:6791811 | Doi | 10.1002/jbmr.2936 |
| Citation | Li X, et al. (2017) FGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPARalpha and PPARgamma Agonists. J Bone Miner Res 32(4):834-845 |
| abstractText | Results of prior studies suggest that fibroblast growth factor 21 (FGF21) may be involved in bone turnover and in the actions of peroxisome proliferator-activated receptor (PPAR) alpha and gamma in mice. We have conducted independent studies to examine the effects of FGF21 on bone homeostasis and the role of FGF21 in PPARalpha and gamma actions. High-fat-diet-induced obesity (DIO) mice were administered vehicle or recombinant human FGF21 (rhFGF21) intraperitoneally at 0 (vehicle), 0.1, 1, and 3 mg/kg daily for 2 weeks. Additional groups of DIO mice received water or 10 mg/kg rosiglitazone daily. Mice treated with rhFGF21 or rosiglitazone showed expected metabolic improvements in glucose, insulin, and lipid levels. However, bone loss was not detected in rhFGF21-treated mice by dual-energy X-ray absorptiometry (DXA), micro-CT, and histomorphometric analyses. Mineral apposition rate, a key bone formation parameter, was unchanged by rhFGF21, while significantly decreased by rosiglitazone in DIO mice. Bone resorption markers, OPG/RANKL mRNA expression, and histological bone resorption indices were unchanged by rhFGF21 or rosiglitazone. Bone marrow fat was unchanged by rhFGF21, while increased by rosiglitazone. Furthermore, FGF21 knockout mice did not show high bone mass phenotype. Treatment with PPARalpha or PPARgamma agonists caused similar metabolic effects in FGF21 knockout and wild-type mice. These results contrast with previous findings and suggest that FGF21 is not critical for bone homeostasis or actions of PPARalpha and PPARgamma. (c) 2016 American Society for Bone and Mineral Research. |
